In Vivo Activity and Pharmacokinetics of Nemorosone on Pancreatic Cancer Xenografts

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Wolf, Robert J ^a,c   Hilger, Ralf A ^b   Hoheisel, Jörg D ^a   Werner, Jens ^c   Holtrup, Frank ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CYTOCHROME P450 3A4; GEMCITABINE; HYPERFORIN; KI 67 ANTIGEN; NEMOROSONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INDUCTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPHENONES; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CARCINOMA; CASPASE 3; CYTOCHROME P-450 CYP3A; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION; HALF-LIFE; HEPATOCYTES; HUMANS; INJECTIONS, SUBCUTANEOUS; KI-67 ANTIGEN; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PHLOROGLUCINOL; PRIMARY CELL CULTURE; TERPENES; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883500554     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074555     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A, (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi:10.3322/caac.21166. PubMed: 23335087.
2. Keleg S, Büchler P, Ludwig R, Büchler MW, Friess H, (2003) Invasion and metastasis in pancreatic cancer. Mol Cancer 2: 14. doi:10.1186/1476-4598-2-14. PubMed: 12605717.
3. Burris H, Storniolo AM, (1997) Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 33 (Suppl 1):: S18-S22. doi:10.1016/S0959-8049(97)90088-5. PubMed: 9166095.
4. Ciochina R, Grossman RB, (2006) Polycyclic polyprenylated acylphloroglucinols. Chem Rev 106: 3963-3986. doi:10.1021/cr0500582. PubMed: 16967926.
5. Leuner K, Kazanski V, Müller M, Essin K, Henke B, et al. (2007) Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J 21: 4101-4111. doi:10.1096/fj.07-8110com. PubMed: 17666455.
6. Schempp CM, Kirkin V, Simon-Haarhaus B, Kersten A, Kiss J, et al. (2002) Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene 21: 1242-1250. doi:10.1038/sj.onc.1205190. PubMed: 11850844.
7. Donà M, Dell'Aica I, Pezzato E, Sartor L, Calabrese F, et al. (2004) Hyperforin inhibits cancer invasion and metastasis. Cancer Res 64: 6225-6232. doi:10.1158/0008-5472.CAN-04-0280. PubMed: 15342408.
8. Hostanska K, Reichling J, Bommer S, Weber M, Saller R, (2003) Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur J Pharm Biopharm 56: 121-132. doi:10.1016/S0939-6411(03)00046-8. PubMed: 12837490.
9. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, et al. (2000) St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 97: 7500-7502. doi:10.1073/pnas.130155097. PubMed: 10852961.
10. Díaz-Carballo D, Malak S, Bardenheuer W, Freistuehler M, Reusch HP, (2008) Cytotoxic activity of nemorosone in neuroblastoma cells. J Cell Mol Med 12: 2598-2608. doi:10.1111/j.1582-4934.2008.00232.x. PubMed: 18194446.
11. Díaz-Carballo D, Malak S, Freistühler M, Elmaagacli A, Bardenheuer W, et al. (2008) Nemorosone blocks proliferation and induces apoptosis in leukemia cells. Int J Clin Pharmacol Ther 46: 428-439. PubMed: 18793585.
12. Holtrup F, Bauer A, Fellenberg K, Hilger RA, Wink M, et al. (2011) Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Br J Pharmacol 162: 1045-1059. doi:10.1111/j.1476-5381.2010.01125.x. PubMed: 21091652.
13. Boven E, Schipper H, Erkelens CA, Hatty SA, Pinedo HM, (1993) The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 68: 52-56. doi:10.1038/bjc.1993.285. PubMed: 8318420.
14. Tanswell P, Koup J, (1993) TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program. Int J Clin Pharmacol Ther Toxicol 31: 514-520. PubMed: 8262691.
15. Kivistö KT, Kroemer HK, Eichelbaum M, (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40: 523-530. doi:10.1111/j.1365-2125.1995.tb05796.x. PubMed: 8703657.
16. Honkakoski P, Negishi M, (2000) Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 347: 321-337. doi:10.1042/0264-6021:3470321. PubMed: 10749660.
17. Tompkins LM, Wallace AD, (2007) Mechanisms of cytochrome P450 induction. J Biochem Mol Toxicol 21: 176-181. doi:10.1002/jbt.20180. PubMed: 17936931.
18. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V, (2006) Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 62: 225-233. doi:10.1007/s00228-006-0096-0. PubMed: 16477470.
19. Simpkins NS, Holtrup F, Rodeschini V, Taylor JD, Wolf R, (2012) Comparison of the cytotoxic effects of enantiopure PPAPs, including nemorosone and clusianone. Bioorg Med Chem Lett 22: 6144-6147. doi:10.1016/j.bmcl.2012.08.023. PubMed: 22944119.
20. Gerhäuser C, (2005) Beer constituents as potential cancer chemopreventive agents. Eur J Cancer 41: 1941-1954. doi:10.1016/j.ejca.2005.04.012. PubMed: 15953717.
21. Cui Y, Gurley B, Ang CY, Leakey J, (2002) Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Anal Technol Biomed Life Sci 780: 129-135. doi:10.1016/S1570-0232(02)00439-7. PubMed: 12383488.
22. Biber A, Fischer H, Römer A, Chatterjee SS, (1998) Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31 (Suppl 1):: 36-43. doi:10.1055/s-2007-979344. PubMed: 9684946.
23. Cui Y, Ang CY, Beger RD, Heinze TM, Hu L, et al. (2004) In vitro metabolism of hyperforin in rat liver microsomal systems. Drug Metab Dispos 32: 28-34. doi:10.1124/dmd.32.1.28. PubMed: 14709617.
24. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, et al. (2003) 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 42: 1430-1438. doi:10.1021/bi0268753. PubMed: 12578355.
25. Iyer M, Reschly EJ, Krasowski MD, (2006) Functional evolution of the pregnane X receptor. Expert Opin Drug Metab Toxicol 2: 381-397. doi:10.1517/17425255.2.3.381. PubMed: 16863441.
26. Takegoshi S, Jiang S, Ohashi R, Savchenko AS, Iwanari H, et al. (2009) Protein expression of nuclear receptors in human and murine tissues. Pathol Int 59: 61-72. doi:10.1111/j.1440-1827.2008.02330.x. PubMed: 19154258.